NASDAQ: HURATuhura Biosciences Inc Stock
$2.43-0.05 (-2.02%)
Updated Sep 17, 2025
HURA Price
$2.43
Fair Value Price
N/A
Market Cap
$121.61M
52 Week Low
$1.80
52 Week High
$8.40
P/E
-0.83x
P/B
6.25x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$30.70M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.78
Operating Cash Flow
-$20M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HURA Overview
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HURA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
HURA
Ranked#180 of 479
Ranked#180 of 479
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.05 | A | |
| $7.70 | A | |
| $34.22 | A |
Be the first to know about important HURA news, forecast changes, insider trades & much more!
HURA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HURA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HURA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HURA is poor value based on its book value relative to its share price (6.25x), compared to the US Biotechnology industry average (4.69x)
P/B vs Industry Valuation
HURA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HURA due diligence checks available for Premium users.
Valuation
HURA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.83x
Industry
-97.28x
Market
37.36x
HURA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.25x
Industry
4.69x
HURA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HURA's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.5M
Profit Margin
0%
HURA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$34.6M
Liabilities
$15.2M
Debt to equity
0.78
HURA's short-term liabilities ($15.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HURA's short-term assets ($12.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HURA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HURA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.2M
Investing
-$156.5k
Financing
$8.7M
HURA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HURA vs Biotech Stocks
Tuhura Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.